Future Prospects of

 

 

ORISCON BIOTECH INDIA PVT LTD

 

 

                                  

                       Oriscon  Biotech  (I)  Pvt  Ltd 


           

Research and development has always taken the back seat amongst Indian pharmaceutical

companies. In order to stay competitive in the future, Oriscon Biotech (I) Pvt Ltd will have to

refocus and invest heavily in R&D.

 

Oriscon Biotech also needs to take advantage of the recent advances in biotechnology and

information technology. The future of the industry will be determined by how well it markets

its products to several regions and distributes risks, its forward and backward integration

capabilities, its R&D, its consolidation through mergers and acquisitions, co-marketing and

licensing agreements.

 

Quality management System :

 

 

Oriscon Biotech India Private Limited, will have to build its own

Quality Management system, which includes Quality Management,

Quality Assurance and Quality Control in the all related wings of

Pharmaceutical Business .

 

Your company " ORISCON BIOTECH (I) PVT LTD " is dedicated 

to provide consistently High Quality Products in the field of Health

care to the satisfaction of medical profession and the consumers

at most economical price. This is being achieved by cumulative

efforts from the top management to the lowest cadre of the

workmen by maintaining preset working standards aimed

at Defect prevention rather than Defect Detection".

 

"ORISCON BIOTECH INDIA PRIVATE LIMITED" is declaring its :

 

 

Responsibility of Quality Assurance:

 

 

Your company's Quality Assurance Department functions

independently to attain the specified standards. Production

and Control operations are clearly specified in written procedures

to meet the requirements of GMP. The responsibility of QA are

Line clearances, Batch Record Review, In-process checks,

investigation of deviations, self inspection, Trainings, Handling

of market complaints, preparation of documents and their

distribution to various departments etc.

 

 

There are written specifications for all incoming materials like

Raw materials, packing materials and finished product.

Pharmacopoeias such as IP, BP, and USP, NF are taken as

standards for Raw  materials, and for all packing materials standard.

 

 

However when a new vendor is to be approved,

Oriscon Biotech Private  Limited has written down procedures

for approval of new vendors. Stability study of the product

is done when there is a change in manufacturer of critical

materials like active ingredients,  Primary Packing materials

& any critical equipments.

 

 

All finished products are tested to the specified standards as

given in specification. The products are subjected to chemical

and microbiological analysis for total counts of microbes and

absence of pathogenic organisms. The products are  released

for dispatch after compliance of the products to the specified

standards.

 


ADVANTAGE

ORISCON  BIOTECH  INDIA  PRIVATE  LIMITED

 

Competent workforce:

 

Your Company  has a pool of personnel with high managerial and

technical competence as also skilled workforce. It has an educated hard working field

force personal in the marketing area and  professional environment to work for.

 

Cost-effective :

Your company's track record of development, particularly in the area of

improved cost-beneficial marketing strategy for various drug molecules is excellent. It

provides a wide variety of generic drugs and sophisticatedly made drug formulations.

Technology:

Your company  has intended to develop a good marketing network of

world-class by investing a lot to establish and strengthen the area in Information Technology.

Globalisation:

Your company is committed to tap the market economy of pharmaceutical

sector and . Above all, it has a clear cut strategy to take a big share of pharma  market,

which is continuously growing at the rate of 18% annually.

Consolidation:

For the first time in many years, your company is finding great opportunities

in pharmaceutical marketing . The process of consolidation, which has become a

generalized phenomenon in the world pharmaceutical industry, has started taking place

in India.

THE GROWTH SCENARIO

India's US$ 3.1 billion pharmaceutical industry is growing at the rate of 18 percent per year.

It is one of the largest and most advanced among the developing countries.

Over 20,000 registered pharmaceutical manufacturers exist in the country.

The domestic pharmaceuticals industry output is expected to exceed Rs460 billion

in the financial year (2010-11), which accounts for merely 2.3% of the global pharmaceutical sector.

STEPS TO STRENGTHEN  ORISCON  BIOTECH ( I )  PVT   LTD

Your  company need to attain the right product-mix for sustained future growth.

Core competencies will play an important role in determining the future prospects

of your company among pharmaceutical companies in the post product-patent regime

after 2005.

Oriscon Biotech (I) Pvt Ltd, in an effort to consolidate its position, will have to increasingly

look at merger and acquisition options of either companies or products. This would help

your company to offset loss of new product options, improve its R&D efforts and improve

distribution to penetrate markets.